Trials / Completed
CompletedNCT04016077
A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of PF-06651600 in Subjects With Hepatic Impairment and Healthy Volunteers
A PHASE 1, NON-RANDOMIZED, OPEN LABEL, MULTIPLE DOSE STUDY TO EVALUATE THE PHARMACOKINETICS, SAFETY AND TOLERABILITY OF PF 06651600 IN SUBJECTS WITH HEPATIC IMPAIRMENT AND IN HEALTHY SUBJECTS WITH NORMAL HEPATIC FUNCTION
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 18 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to characterize the effect of hepatic impairment on the pharmacokinetic(s) (PK) of PF-06651600 following administration of multiple once daily doses of PF-06651600. The safety and tolerability of PF-06651600 will also be evaluated in this study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PF-06651600 30 mg | PF-06651600 in 10 mg oral tablets will be administered on days 1 to 10. |
Timeline
- Start date
- 2019-07-19
- Primary completion
- 2020-03-05
- Completion
- 2020-03-05
- First posted
- 2019-07-11
- Last updated
- 2021-04-08
- Results posted
- 2021-04-08
Locations
2 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04016077. Inclusion in this directory is not an endorsement.